Epidemiological clues and genotyping data from tens of thousands of individuals with or without Alzheimer's led to an age-specific polygenic risk score.
A pilot program will allow 100 individuals and families with a rare form of epilepsy to receive exome sequencing as part of a larger epilepsy genetics database effort.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
Researchers for the InPSYght project are sequencing 10,000 genomes and generating linked-read data for 500 to better understand schizophrenia and bipolar disorder.
The study will involve assaying proteomic markers for dementias including Alzheimer's disease, and understanding genomic markers as part of the normal aging process.
Two studies described de novo gene mutations involved in autism spectrum disorder and other neurodevelopmental conditions, while weeding out unrelated changes.
University of Pennsylvania researchers found that patients with autism had a greater mutational burden in essential genes than their unaffected siblings.
The company plans to release its first product in this area, a blood-based proteomic diagnostic for epilepsy, as a laboratory-developed test next year.
